Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma

por Sirohi, B, Powles, R, Kulkarni, S, Rudin, C, Saso, R, Rigg, A, Horton, C, Singhal, S, Mehta, J, Treleaven, J
Publicado 2001

Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients

por O'Brien, M E R, Borthwick, A, Rigg, A, Leary, A, Assersohn, L, Last, K, Tan, S, Milan, S, Tait, D, Smith, I E
Publicado 2006

Guy’s cancer cohort – real world evidence for cancer pathways

por Moss, C., Haire, A., Cahill, F., Enting, D., Hughes, S., Smith, D., Sawyer, E., Davies, A., Zylstra, J., Haire, K., Rigg, A., Van Hemelrijck, M.
Publicado 2020

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.

por Rigg, A., Cunningham, D., Gore, M., Hill, M., O'Brien, M., Nicolson, M., Chang, J., Watson, M., Norman, A., Hill, A., Oates, J., Moore, H., Ross, P.
Publicado 1997